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An array of phenotypically diverse myeloid cells and macrophages (MC&M) resides in the
tumor microenvironment, requiring multiplexed detection systems for visualization. Here
we report an automated, multiplexed staining approach, named PLEXODY, that consists
of five MC&M-related fluorescently-tagged antibodies (anti - CD68, - CD163, - CD206, -
CD11b, and - CD11c), and three chromogenic antibodies, reactive with high- and low-
molecular weight cytokeratins and CD3, highlighting tumor regions, benign glands and
T cells. The staining prototype and image analysis methods which include a pixel/area-
based quantification were developed using tissues from inflamed colon and tonsil and
revealed a unique tissue-specific composition of 14 MC&M-associated pixel classes.
As a proof-of-principle, PLEXODY was applied to three cases of pancreatic, prostate
and renal cancers. Across digital images from these cancer types we observed 10
MC&M-associated pixel classes at frequencies greater than 3%. Cases revealed higher
frequencies of single positive compared to multi-color pixels and a high abundance of
CD68+/CD163+ and CD68+/CD163+/CD206+ pixels. Significantly more CD68+ and
CD163+ vs. CD11b+ and CD11c+ pixels were in direct contact with tumor cells and T
cells. While the greatest percentage (∼70%) of CD68+ and CD163+ pixels was 0–20
microns away from tumor and T cell borders, CD11b+ and CD11c+ pixels were detected
up to 240 microns away from tumor/T cell masks. Together, these data demonstrate
significant differences in densities and spatial organization of MC&M-associated pixel
classes, but surprising similarities between the three cancer types.
Keywords: multiplex, immunofluorescence, immunohistochemistry, macrophage, myeloid, spatial profiling, FFPE
INTRODUCTION
Diverse subsets of myeloid cells and macrophages (MC&M) are observed in tissues, including
both resident and recruited MC&M populations (1–3). MC&Ms are tissue-specific and change
in response to infection, inflammation and cancer (4). Macrophages are first produced by
erythromyeloid progenitors in the yolk sac and populate the tissues of the developing embryo (5).
A broader range of myeloid cells subsequently arises from hematopoietic stem cells in the fetal
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liver, and then in the bone marrow after birth (6). Some
MC&M subtypes are short-lived and replaced frequently by
newly recruited cells, whereas others can persist in tissues
for years and are maintained by self-renewal (7). While the
functional programming of MC&M subpopulations is influenced
by their origins, they can further differentiate or become activated
in tissues in response to organ-specific microenvironmental
factors (8). Monocytes recruited to inflamed tissues can for
instance become inflammatory macrophages or monocyte-
derived dendritic cells (9), and myeloid cells produced in
the bone marrow of tumor-bearing mice and humans can
colonize the tumor microenvironment (TME) and develop
immunosuppressive activities (10). The immune infiltration of
cancers consists of a complicated admixture of tissue and organ
resident MC&M populations as well as MC populations from the
bone marrow whose production, attraction and phenotypes in
the TME are influenced by tumor-derived cytokines.
Immunohistochemistry (IHC) and immunofluorescence (IF)
can be used to visualize MC&M populations in formalin fixed
and paraffin embedded (FFPE) tissue sections based on the
expression of cluster definition (CD) antigens. IF is best suited
to accurately analyze co-expressed CD markers, while IHC offers
greater morphologic and diagnostic accuracy. Phenotypically
distinct MC&M subtypes differ in immune function, response to
stimuli regulating chemotaxis and differentiation, and cytokine
secretion. While links between phenotype, differentiation and
functionality have been established for murine macrophages,
the human MC&M compartment remains less well understood
(11). In the realm of diagnostic pathology, CD68 and CD163
are established markers of macrophages (12). CD68 is expressed
by classically activated, inflammatory, M1 macrophages, while
CD163 marks alternatively activated, proangiogenic and
prooncogenic M2 macrophages (13). CD163+ macrophages
in tumor regions are also referred to as tumor associated
macrophages (TAM) (14, 15). The observation of CD68 and
CD163 expression in TAMs (16) raised the possibility of a
dynamic process underlying M1 and M2 polarization (15, 17).
Further, the dynamics of macrophage polarization suggest
that phenotypic M1/M2 classification with single markers is
simplistic and that multiple, functionally distinct subgroups
may exist within the CD68+ and CD163+ macrophage
populations. Notably, switching TAMs from M2 to M1
represents a key anti-cancer immunotherapeutic treatment
strategy (18).
In addition to TAMs, other subtypes of myeloid cells populate
the TME. These include: (i) angiopoietin-2 (Ang-2) receptor,
Tie2, expressing monocytes (TEM), (ii) myeloid-derived
suppressor cells (MDSC), (iii) tumor-associated neutrophils
(TAN), and (iv) tumor- associated dendritic cells (TADC) (19).
Similar to TAMs, CD11b+ monocytic and granulocytic MDSCs
promote metastatic tumor progression and suppress the immune
response to the tumor. In contrast, CD11c+ macrophages
regulate innate and adaptive immune responses and play a
major role in the treatment response to PD-L1 targeting immune
checkpoint inhibition (20).
Phenotypic profiling of the tumor immune response provides
important information for tumor sub-classification, treatment
decisions and clinical outcome prediction (21–24). Thus, it is
imperative to have good and reliable tools to detect immune
cell subtypes in tumor samples. We took advantage of the
TissueFaxs PLUS instrument, which can be used for multi-
color tissue cytometry (25). The TissueFaxs allows acquisition
of data from up to 10 fluorophores and to gate cells based
on marker expression, shape or size characteristics (26). The
use of filter cubes enables color separation and simplifies the
optimization of multiplex panels that consist of bright and dim
antibody signals (27, 28). In addition, improvements in analysis
of digital images using masks over cells and regions (29, 30) and
advances in open source and commercial image analysis software
have opened the door to data extraction from digital images
(31). For example, measuring distances between cells in whole
slides recently demonstrated how immune checkpoint inhibition
changes the organization of T cell subsets in lung cancer, and
that distance between T cells and cancer cells was associated with
patient outcome (32).
In immunophenotyping studies, CD8+ T cells have been the
primary focus, because of their direct cytotoxicity toward cancer
cells and cytotoxic activation through PD-1/PD-L1 checkpoint
inhibition (33–36). While CD8+ T cells are regulated by
MC&Ms, the systematic profiling of and immunophenotyping of
MC&Ms by tissue imaging has not advanced as rapidly as that of
T cells. To fill the much-needed technological gap, we combined
antibodies reactive toward M1 and M2 macrophages, myeloid
cells and dendritic cells (CD68, CD163, CD11b, and CD11c,
respectively) into one fluorescently-tagged antibody panel (mIF)
panel and included CD206 as a functional M2 macrophage
marker. Here, we demonstrate the feasibility of an automated
staining process for whole slides with eight antibodies. The assay,
named PLEXODY, incorporates automated multiplexed IF (mIF)
and multiplex IHC (mIHC) tissue staining, digital image co-
registration and data extraction and combines the quantitative
strength of IF with the diagnostic capacity of IHC. As a proof
of principle, we applied the PLEXODY assay to tissues from
pancreatic, prostate and renal cancers and investigated its fitness
for the analysis of single positive and multi-color pixels, and
for measurements of MC&M-associated pixel densities and their
proximities to tumor cells and T cells.
MATERIALS AND METHODS
Tissue Resources
Cases for the study were obtained from the pathology archives at
Cedars-Sinai Medical Center by an honest broker in the Biobank
and Translational Research Core. The link to any information
that can be used to identify patients was destroyed and blocks
from each case were labeled with the tissue type and a consecutive
number. Therefore, the study was considered exempt from IRB
oversight by the IRB committee (IRB # Pro00025521). The de-
identified formalin fixed and embedded paraffin (FFPE) blocks
were transferred to the research core and sectioned by the
core personnel. Slides were labeled with the tissue type and
a consecutive number. Unstained slides were provided for the
project without any accompanying data.
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Immune Cell Phenotyping in FFPE Tissues
Using a Multiplex Antibody Format
Antibodies
The staining with a sequence of 5 antibodies was completed
on the Ventana Discovery Ultra autostainer. The antibodies
were CD68 (clone KP-1 mouse mAb, Ventana Medical Systems
cat. 790-2931), CD11c (clone EP1347Y rabbit mAb, Abcam cat.
ab52632), MRC1 (CD206) (clone CL0387 mouse mAb, Sigma-
Aldrich cat. AMAb90746), CD163 (clone MRQ26 mouse mAb,
Ventana Medical Systems cat. 760-4437) and CD11b (clone
EPR1344 rabbit mAb, Abcam cat. ab133357).
Antibody Optimization
Several parameters were optimized for each antibody in
the multiplex IF assay. (1) Antibody–fluorophore pairs were
determined based on staining intensities of fluorophores and
expression levels of respective antigens. The pairs are: CD68–
Discovery Cy5 Kit (Ventana Medical Systems cat. 760-238),
CD206–Discovery DCC Kit (Ventana Medical Systems cat. 760-
240), CD163–Discovery FAM Kit (Ventana Medical Systems
cat. 760-243), CD11c–Discovery Red 610 Kit (Ventana Medical
Systems cat. 760-245), and CD11b–Discovery Rhodamine 6G
Kit (Ventana Medical Systems cat. 760-244). The secondary
antibodies were Discovery OmniMap anti-mouse HRP (Ventana
Medical Systems cat. 760-4310) and Discovery OmniMap anti-
rabbit- HRP (Ventana Medical Systems cat. 760-4311). (2)
Antibody dilutions are optimized using IHC. IHC and IF used
the amplification system with similar efficiency. This allowed
a smooth transition from IHC to fluorescent detection. (3) To
determine the sensitivities of antibodies to heat induced epitope
retrieval (HIER), staining intensities were compared for one
vs. five HIER steps prior to incubation with each antibody
on a separate slide. The top 10% of the histogram of staining
intensity by an antibody after 1 retrieval was compared to
the top 10 percent of the histogram after 5 retrievals. (4) To
confirm that antibodies are completely removed through heat
denaturation after staining, each antibody was visualized first
with the yellow chromogen, denatured, washed away. The slide
was then incubated with secondary antibody and red chromogen.
Intensities of red pixels were compared in slides without and
with removal of the antibody. If an antibody could not be fully
removed, such as the pan-CK antibody, it was used last in the
staining sequence.
Immunofluorescent Staining
The Ventana Discovery Ultra autostainer was used for staining
and antigen retrieval was performed on the deparaffinized slides
with Cell Conditioning 1 (CC1) solution (Ventana Medical
Systems cat. 950-124) for 64min at 95◦C. All antibody incubation
steps occurred at 37◦C, primary antibodies were incubated
for 32min and secondary antibodies for 12min. First, slides
were blocked with Discovery Inhibitor for 12min. The CD11b
antibody was applied first at a 1:2000 dilution and visualized with
the Discovery Rhodamine 6G Kit. Antibody denaturation was
performed with Cell Conditioning 2 (CC2) solution (Ventana
Medical Systems cat. 950-123) for 8min at 91◦C. Next, the
CD206 antibody was applied at a 1:500 dilution and visualized
with the Discovery DCC Kit. Antibody denaturation was again
performed with CC2 solution for 8min at 91◦C. Next, the CD11c
antibody was applied at a 1:500 dilution and visualized with
the Discovery Red 610 Kit. Antibody denaturation was again
performed with CC2 solution for 8min at 91◦C. Next, the
CD68 antibody was applied and visualized with the Discovery
Cy5 Kit. Antibody denaturation was again performed with CC2
solution for 8min at 91◦C. Lastly, the CD163 antibody was
applied and visualized with the Discovery FAM Kit. The slide
was then counterstained with DAPI (0.1µg/ml, Thermo Fisher
Scientific cat. D3571) and cover slipped with ProLong Gold
antifade reagent (Life Technologies cat. P36930).
Imaging of Fluorescent Slides
Slides stained with the multiplex IF (mIF) panel were imaged
with a TissueFaxs whole slide scanning platform (TissueGnostics
USA Ltd, Tarzana, CA) equipped with a 20x objective and a
scientific-grade 16-bit monochromatic camera (1392 × 1040
pixel). Each fluorophore was measured using a separate filter
cube corresponding to its emission wavelength. DAPI (Chroma,
cat. 49000), FITC/CY2 (Chroma, cat. 49002), Cy5 (Chroma, cat.
49006), Gold (Chroma, cat. 49304), Red (Chroma, cat. # 49008),
and Aqua (Chroma, cat. 49302). The pixel size of the TissueFaxs
is 0.3× 0.3µm. Scanned regions are saved as tiles in a lossless jpg
format.
The IF stain consists of 5 colors + DAPI that are separately
acquired by the TissueFaxs and the output is a gray level image
for each fluorophore. The areas for analysis were selected by the
study pathologist (BSK) using an adjacent hematoxylin and eosin
stained slide as a reference. The pathologist’s annotation was
transferred to the fluorescent preview image in the TissueFaxs
software and the regions of interest were selected for high
resolution imaging using the software’s marking tools.
IHC Staining After IF Staining
Coverslips were removed from slides after all fluorescent images
were captured and the slides were placed on the Ventana
Discovery Ultra autostainer. Reagents were purchased form
Ventana Medical Systems unless indicated otherwise. Antibody
denaturation was performed on the slides with CC2 solution
for 8min at 91◦C. The slides were blocked with Discovery
Inhibitor CM (a component of the Discovery ChromoMap DAB
kit) for 12min. All primary and secondary antibody incubations
are conducted at 37◦C. All primary antibodies were obtained
in a prediluted formulation from Ventana and incubated for
32min. Prediluted secondary antibodies conjugated to haptens
(HQ or NP) were incubated for 16min. The anti-hapten
antibodies conjugated to horse radish peroxidase (anti HQ-
HRP) or alkaline phosphatase (anti-NP-AP) were incubated for
16min. The CD3 (clone 2GV6 rabbit mAb, cat. 790-4341), high
molecular weight cytokeratin (HMW-CK) (Ventana CONFIRM
anti-keratin mouse monoclonal (clone 34ßE12, cat. 790-4373)
and low molecular weight cytokeratin 8/18 (LMW-CK) (pre-
diluted cytokeratin 8 & 18 (clones B22.1 & B23.1), cat. 760-
4344) were used with Discovery Teal HRP Kit (RUO) (cat. 760-
247), Discovery Purple Kit (RUO) (cat. 760-229), and Discovery
Yellow Kit (RUO) (cat. 760-239) chromogen kits, respectively.
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The slide was counterstained withModifiedMayer’s Hematoxylin
(American MasterTech cat. HXMMH100) and cover-slipped
with the toluene free mounting medium EcoMount (BIOCARE
Medical cat. EM897L).
Digital Imaging of IHC Slides
Upon completion of the staining the slides were scanned at
20x magnification using the Vectra 2 (PerkinElmer Life and
Analytical Sciences, Boston, MA). The spectral image consists
of λ-stacks captured with an acusto-optic tunable filter in the
spectral λ range between 420 and 700 nm with 20 nm resolution.
The system is equipped with an 8-bit monochromatic camera
and a 20X objective, and each image plane in the λ-stack has
1392 × 1040 pixels. The exposure time was 4ms, and a 1 × 1
pixel binning was used for image acquisition (Nuance acquisition
software, Perkin-Elmer). A flat-field correction was applied to
prepare the cube for digital unmixing of chromophore colors.
The pixel size of the Vectra systems is 0.5 × 0.5µm. To separate
the chromogenic signals, the raw spectral image stacks were
imported into the InFormTM 2.0 tissue image analysis software
(Perkin-Elmer, WalthamMA). Using a spectral library generated
from single stains of each chromogen color, the images were
unmixed and individual chromophore images were separated by
the InFormTM software. Image visualization was accomplished
by a multi-layer tiff image. After the spectral unmixing, a mask
was generated using Matlab R2016a (Mathworks, Natick, MA)
which included labels of cancerous and benign areas of the tissue
as well as empty parts of the tile. Gray scale images of individual
chromophores were used for downstream analysis.
Cancer Cell and T Cell Masks in IHC Images
Binary masks of cancer cells and T-cells were generated from
unmixed images of IHC slides. The mask of cancer cells was
obtained through the machine learning module built into the
InForm ver. 2.0 software. Themodule was trained by the operator
to automatically delineate the cancer epithelium. Fifty small
cancer areas were randomly selected from across all slides to
train the algorithm. The trained module was applied to image
tiles from IHC slides and yielded binary masks with cancer
epithelium in the foreground (white pixels) and the remaining
tissue components in the background (black pixels). The cancer
cell mask was transferred via image registration to IF stained
slides.
IF and IHC Image Co-registration
We implemented the affine image co-registration procedure (37)
to transfer the tumor or T cell masks from the IHC to the
corresponding IF images based on nuclear staining intensities
of hematoxylin and DAPI. The unmixed hematoxylin mask
from the IHC and the DAPI mask from the IF were used
in the co-registration procedure and to determine the co-
registration transformation matrix (37). The matrix contains a
set of parameters that control the transfer and alignment of the
images. After establishing the co-registration parameters, masks
were automatically transferred for all tiles in a case. The co-
registered area in each tile was used to generate tumor and T cell
masks analyzed for densities of CD68+, CD163+, CD11b+, and
CD11c+ pixels.
Thresholding IF Staining and Pixel Area
Quantification
The gray scale images of the IF images were thresholded
using Matlab software. Thresholds were visually adjusted using
multiple images from each cancer type. After thresholding, a
binary image was created for each channel and image tile and
positive pixel were enumerated. Pixel numbers were exported
together with the area from which they were obtained. Pixel
groups with fewer than 9 pixels were excluded from the analysis.
Nuclear Segmentation and Cell Phenotyping
A nuclear segmentation algorithm was applied to hematoxylin
or DAPI images to outline nuclei and to output a nuclear mask.
The nuclear outline was expanded into a doughnut by a fixed
length equal to 1/3 of the mean nuclear radius and positive pixels
were counted within the doughnut. If the positive pixel density
exceeded a predefined threshold, the cell was classified as positive.
The process was repeated for all antibody channels (38, 39).
Comparing Cell-Based and Pixel/Area-Based
Segmentation Approaches
The positive pixels were detected in the field of view (FOV)
by fluorescence intensity thresholding using the same threshold
value for pixel- and cell-based segmentation methods. The
experiment was carried out using tiles from inflamed colon
mucosa (n = 28) and correlations between pixels and nuclear
counts were evaluated using the Pearson correlation coefficient.
Pixel Designations in MC&M Populations
We used the binary masks from the pixel-based segmentation
approach to analyze macrophage populations. The segmentation
of pixels was performed in Matlab and the segmented pixels
were stratified into several masks. The MC&M-mask consists
of the union of positive pixels from all antibodies, while the
other masks originate from individual antibodies. Pixels in these
antibody masks possess one or more colors. Pixels in the CD68-
mask and CD163-mask are divided into single, double and triple
positive pixels, which are counted separately. A small number of
residual pixels that are positive for 4 or 5 antibodies is not further
separated.
Single positive pixels
Single positive pixels are pixels colored exclusively only by one
of the antibodies. They are counted after excluding double and
higher order labeled pixels from individual antibody masks.
Double positive pixels
Double positive pixels are pixels positive for two antibodies.
They are generated by the intersection of two masks. Labels
include CD68+/CD163+, CD68+/CD11b+, CD68+/CD11c+,
CD163+/CD11b+, CD163+/CD11c+, CD11b+/CD11c+.
Double positive pixels may contain small subgroups of triple and
quadruple positive pixels.
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Triple positive pixels
Triple positive pixels are pixels positive for three or more
antibodies. They are identified by the overlap of pixels of 3 masks
and contain a small population of 4 and 5 color positive pixels.
Pie-Charts
Pie charts in Figure 4A consist of single positive CD68+,
CD163+, CD11b+, CD11c+, and P2,3,4,5 pixel groups. For each
pixel class, the average across all the tiles from a case is calculated
and shown in the pie-chart. The related standard deviations are
listed in Supplementary Tables.
Pie charts in Figure 4B illustrate in detail the double positive
and higher order populations shown in Figure 4A. Double
positive pixels are obtained directly from dichotomized gray-
scale images using a Matlab code and by overlaying two
individual color masks. Higher order pixel numbers are obtained
by subtracting single and double positive pixels from theMC&M-
mask.
Pie charts in Figures 4C,D illustrate single and multicolor
pixel populations underneath CD68-masks or CD163-masks.
Double positive pixel populations include CD68+/CD163+,
CD68+/CD11b+, CD68+/CD11c+ and CD163+/CD11b+,
CD163+/CD11c+. Triple positive pixel populations include
CD68+/CD163+/CD206+, CD68+/CD11b+/CD11c+ and
CD163+/CD11b+/CD11c+. All other triple positive and
quadruple positive pixels exist at a frequency below 3.0% and are
not included in the pie-charts.
Measuring Densities and Distances
Densities of pixels belonging to CD68, CD163, CD11b, and
CD11c-masks were measured inside and outside the tumor mask
and underneath the T cell mask. In mIF and mIHC co-registered
images, the number of each pixel color was dived by the number
of cytokeratin positive pixels (tumor area). MC&M pixel groups
of fewer than 9 pixels were excluded from the analysis.
We measured two types of distances: between MC&M pixels
and tumor cells, and between MC&M pixels and T cells. To
measure the distances, we identified tumor cell nuclei located at
the tumor periphery in mIF/mIHC co-registered images. These
nuclei were identified by first overlaying the tumor mask on
the nuclear mask from the IHC slides and then excluding all
nuclei not located within a region demarcated at the edge of
the tumor mask by an isometric line. The tumor border region
was transferred to individual IF images to measure the distances
between tumor nuclei and MC&M pixels.
To find the closest group of MC&M pixels to each tumor cell
nucleus at the tumor border we wrote an algorithm that employs
two-dimensional Euclidean distance transform and identifies
shortest distance between the nucleus and the closest MC&M
antibody pixel. For each tumor nucleus, four distances were
returned by this algorithm, one for each MC&M antibody.
The same algorithm was used to measure distances between
T cells and MC&M pixel classes. Proximities between MC&M
pixel classes and T cells, and between MC&M pixel classes and
tumor cells were illustrated through distance histograms. The
distances were binned by distance interval (0, 0–20 microns,
20–40 microns etc.).
PLEXODY Assay
This assay consists of the following pipeline: multiplex
IF (mIF) staining→ digital image acquisition (fluorescent
labels)→ multiplex IHC (mIHC) staining→image acquisition
(chromogenic labels)→ co-registration of mIF andmIHC tiles→
digital image analysis and data generation. The data are analyzed
with in house software programs with Matlab.
Statistical Analysis and Data Visualization
Data were analyzed in Microsoft Excel using built in functions
for t-test, Pearson correlation coefficient, and ANOVA. Graphs
for data visualization were generated in Microsoft Excel.
RESULTS
A Multiplex Assay for Myeloid Cells and
Macrophages
To analyze the spatial organization of tumor-associated
myeloid cells and macrophages (MC&M) through visualization
by antibodies, we developed an automated, multiplexed
immunofluorescent assay. We optimized the staining conditions
for anti-CD68, -CD163, -CD206, -CD11b, and -CD11c
antibodies using immunohistochemistry (IHC) and the Ventana
purple substrate, which revealed different staining patterns
of each antibody in tonsilar germinal centers and inflamed
colon mucosa (Figure 1A). The antibody clones used for the
staining are either commonly applied in clinical practice (CD68
and CD163 prediluted Ventana formulations of validated
monoclonal antibodies (40, 41), have been validated by the
vendor (Abcam rabbit monoclonal antibodies CD11b, CD11c),
or have been tested in The Human Protein Atlas (www.
proteinatlas.org). CD68+, CD163+, CD11b+, and CD11c+
cells where observed in tonsil and colon. In contrast, no CD206+
cells were present in the tonsil. However, CD206+ macrophages
were noted in inflamed colon mucosa (Figure 1A). The non-
overlapping staining patterns of MC&M-related antibodies in
tonsil and colon confirm the specificities of the antibodies and
assay conditions.
The multiplex assay consists of sequential staining rounds
on the Ventana autostainer. Each round requires that the
primary and secondary antibodies from the previous round
are completely removed. This is accomplished by heat retrieval
using citrate buffer pH 6.0. The position of the antibody in the
multiplex panel, whether it is the first, second, third, fourth
or fifth antibody is chosen in part, based on the sensitivity of
the epitope to heat retrieval. Therefore, we tested the sensitivity
to heat retrieval for each antibody. As shown in Figure 1B,
none of the antibodies was affected by five rounds of heat
retrieval, simplifying the design of the multiplex panel. Next,
we determined the efficiency of removing antibodies after the
staining cycle, which is another factor that determines the
antibody sequence in the multiplex assay. Staining intensities
before and after removal of each antibody by heat retrieval were
compared. All antibodies were removed, excluding the possibility
that overlapping signals are caused by residual antibody binding
after heat retrieval (Figure 1B, column labeled with “+”).
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FIGURE 1 | Development of the PLEXODY multiplex tissue staining assay. (A)
Antibody staining patterns using chromogenic IHC detection. Panels depict
select regions in tonsil (upper row) or inflamed colon mucosa (lower row)
stained with the antibody listed above each panel. Slides were counterstained
using hematoxylin. Scale bar = 20µm. (B) Sensitivity of antibodies to antigen
retrieval and heat denaturation. Antibody binding was measured by
chromogenic signal intensity in tissues subjected to one or five rounds of
antigen retrieval treatments. The signal intensity in the histogram after one
retrieval was considered 100%. P-values are shown in
Supplementary Table 1. In addition, each antibody was removed by heat
denaturation and the slide was tested for residual antibody binding using the
secondary antibody with a red chromogen. The percentage of signal remaining
after antibody removal is shown as a bar labeled (+). (C) Antibody staining
patterns using mIF. Panels depict a region in tonsil or inflamed colon mucosa.
Slides were counterstained using DAPI. Scale bar = 10µm. (D) Antibody
staining patterns in tonsil. The region of tonsil includes a germinal center (white
outline) and perifollicular zone surrounding the germinal center. Scale bar =
200µm.
As a next step, the chromogenic IHC assay was transferred
to an immunofluorescent (IF) readout and multiplexed
(Figure 1C). Since the amplification of the IHC and IF Ventana
systems are comparable, antibody dilutions and incubation
times remained the same. Individual staining patterns of
antibodies in the IF 5-plex assay mimicked the single antibody
IHC staining patterns in Figure 1A. In addition, changing the
sequence of the antibodies in the panel did not alter staining
patterns, suggesting that the tissue-bound fluorophores are
not causing steric hindrance. Fluorescent slides were scanned
on the TissueFaxs slide scanner using individual filter cubes
that were harmonized with the emission wavelengths of the
Ventana fluorophores. The imaging using filter cubes is not
compromised by the bleed over of fluorophore signals and
can be used with fluorescent signals of different staining
intensities.
As tonsil is commonly used for validation of mIF assays
(28), we compared the staining patterns of the MC&M reactive
antibodies in germinal center and the perifollicular zone
(Figure 1D). CD68+ pixels were abundant in germinal centers,
while CD163+ pixels primarily populated the perifollicular zone.
Both CD11b+ pixels and CD11c+ pixels resided inside germinal
centers and to a lesser extent in the perifollicular zone. Overall,
staining patterns and intensities during assay optimization and
repeated testing of the 5-plex IF antibody panel were consistent
between days.
A Pixel-Based Detection Approach to
Quantify Myeloid Cells and Macrophages
A previous study demonstrated that the nuclear-based image
segmentation method may not accurately report macrophage
numbers after staining with CD68 and CD163 because cellular
processes can reach across long distances from nucleus (42).
Fluorescently labeled cell processes are often in a different
tissue section than the nucleus and an approach involving only
perinuclear analysis will not lead to an acute measurement of
macrophages (Figure 2A). Instead, a pixel-based segmentation
approach, which includes the antibody signal in cellular processes
is better suited for quantification of macrophages. Therefore, we
used the pixel-based segmentation approach to identify positive
pixels after setting a threshold (Figure 2B). Thresholds were
based on the negative isotype controls included in every staining
batch (not shown) and to remove artifacts, groups of fewer than
9 adjacent pixels were excluded from further analysis. Pixels
were converted into a binary positive/negative mask for analysis
(Figure 2C). The area encompassed by positive pixels was
determined. For nuclear based segmentation and classification
as positive or negative, we outlined nuclei in the DAPI channel
and determined the average staining intensity normalized to
area within a doughnut around the nucleus (Figure 2C). To
determine how pixel-based and nuclear segmentation-results
correlated across antibodies, we used 28 tiles of inflamed
colon mucosa to calculate correlation coefficients between
nuclear counts (cell number) and pixel counts (cell area)
(Figure 2D, Supplementary Figure 1). Correlation coefficients
differed for each antibody. The lowest was for CD68 (r =
0.19) and CD11c (r = 0.25), while CD11b revealed good
concordance between nuclear and pixel-based quantification
methods (r = 0.71). As a control, we measured the correlation
for CD3+ T cells, since cellular processes are rare in T
cells and all positive pixels are in the perinuclear region. As
expected, the correlation between the cell and area measurements
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was high (r = 0.98). Thus, we confirmed a previous study
demonstrating that the pixel-based analysis approach is better
suited for quantification of MC&M-associated pixels than
the nuclear segmentation-based method (42) and proceeded
to use the pixel-based segmentation method to analyze the
spatial organization of MC&M-associated antibody staining
patterns.
The pixel-based segmentation can be used to count pixels
that are colored with one, two, three or more antibodies by
overlaying and intersecting individual pixel masks (Figure 2E).
Wemeasured single positive pixel classes (n= 4) only containing
one color. Double positive pixel classes (n = 10), are generated
by the intersection of pixels from two pixel masks and triple
positive pixel classes are obtained by the intersection of three
masks. The CD206 mask is included. Alternatively, a pixel
mask is generated for only one antibody, for example for
CD163, and pixel colors underneath the mask are analyzed
(Figure 2E). There will be single, double, triple and higher
order colored pixels within this CD163-mask, which can be
further quantified. Altogether, the pixel-based segmentation
approach can be used to measure the areas that are occupied
by various pixel classes and to infer spatial locations of MC&M
cells that are marked by these pixels. However, the pixel-based
segmentation approach cannot be used to enumerate MC&M
subpopulations, because to the most part, pixels cannot be
assigned to specific cells and it is unknown whether individual
pixel classes are uniform and consistent within cellular subgroups
MC&Ms.
Next, MC&M populations visualized by the 5-plex assay
were quantified in inflamed colon mucosa and germinal
center of tonsil (Figures 3A,B, Supplementary Figures 2,3). We
measured pixels colored by one or two antibodies and generated
14 separate classes of MC&M-associated pixels. To calculate
the percentage of single and double color pixels, we used
the union of MC&M-associated pixels (MC&M-mask) as the
reference, which is the area in the tissue taken up by all
positive pixels. Eight pixel classes dominated in colon mucosa
compared to six in tonsil germinal center. Further, 55% of
pixels in the colon mucosa were reactive with only one antibody
(single positive pixels) while in the germinal centers 84% of
pixels were single positive (Figures 3C,D). In the colon mucosa,
the most abundant population of single positive pixels was
CD11b+ (20%), while CD68+, CD163+, and CD11c+ pixels
each encompassed approximately 10% of the MC&M mask,
which is the area defined by the intersection of the CD68, CD163,
CD11b, and CD11c colored pixels. In the germinal centers of the
tonsil, CD11b+ single positive pixels amounted to 45% of the
MC&M-mask and the percentage of double positive, P2 pixels
was reduced compared to colon mucosa (Figure 3D).
In inflamed colon, we included CD206+ pixels in the double
positive pixel category. As we observed CD206+ staining in
vascular cells, we only measured CD206+ pixels underneath the
MC&M-mask. The largest pixel fraction was CD163+/CD206+
(Figure 3C, Supplementary Table 2). In contrast to the colon
mucosa, which displayed 10 double positive pixel classes, only 6
double positive pixel classes were observed in the tonsil germinal
center (Figure 3D, Supplementary Table 3). The majority (90%)
FIGURE 2 | Comparison of nuclear and pixel-based segmentation methods.
(A) Schematic image of a lymphocyte (left) and macrophage (right). The
dashed lines represent virtual tissue sections. (B) Gray scale images of
antibodies indicated above each panel. (C) Nuclear segmentation. Nuclei are
outlined in the DAPI DAPI channel. The inner line demarcates the nucleus and
the outer line shows the border of the doughnut used to quantify pixels for
nuclear classification. To count positive pixels, the gray scale image was
converted to a binary mask and thresholded. (D) Correlation between nuclear
and pixel/area-based measurements. MC&M counts obtained through nuclear
segmentation were correlated with MC&M-associated pixel areas obtained by
the pixel-based segmentation. Pearson correlation coefficients (R2) are shown
in the table. (E) Schematic representation of single, double and triple positive
pixel classes. The single positive pixel group reacts with only one of the
(Continued)
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FIGURE 2 | antibodies and consists of pixels stained with only on color. Pixels
in double positive pixel groups, of which 10 classes can be identified, contain
two colors. These pixels are identified by intersecting pixel masks from two
antibodies and extracting those pixels with 2 colors. Triple positive pixels are
obtained by the same process through intersection of binary pixel masks from
three antibodies. (F) Pixel mask of one antibody. Example showing the
CD163-mask. Pixels in this mask can be one, two, three, or more colors.
FIGURE 3 | MC&M-associated pixels in inflamed colon mucosa and tonsillar
germinal centers. (A,C) Colon mucosa. (A) Representative image tile of mIF
5-plex. C. Frequencies of single and double positive MC&M-associated pixel
classes. The MC&M-mask, determined by the intersection of CD68+,
CD163+, CD206+, CD11b+, and CD11c+ pixels, was used as the reference.
Single positive and multicolor (P2, 3, 4, 5) pixel numbers were extracted from
28 tiles and the percentages of MC&M mask are shown in the left stacked bar.
Standard deviations are in Supplementary Table 2. The P2, 3, 4, 5 pixel
classes are further separated into ten two-color MC&M classes and their
percentages are shown in the right stacked bar. (B,D) Germinal center of
tonsil. (B) Representative image tile of mIF 5-plex. (D) Frequencies of single
and double positive MC&M-associated pixel classes. The MC&M-mask,
determined by the intersection of CD68+, CD163+, CD11b+, and CD11c+
pixels, was used as the reference. CD206+ pixels were not observed. Single
positive and multicolor, P2, 3, 4 pixel numbers were extracted from eight tiles
and their percentages of the MC&M-mask are shown in the left stacked bar.
Standard deviations are in Supplementary Table 3. The P2, 3, 4 pixels were
further separated into six two-color MC&M-associated pixel classes and their
percentages are shown in the right stacked bar.
were CD68+/CD11c+ and CD11b+/CD11c+. Interestingly,
despite the large number of CD11b+ pixels, CD68+/CD11b+
pixels were infrequent, suggesting that amount to which pixels
overlap is not related to the abundance of pixels. This observation
suggests that the overlap of pixels is specific and that the size
of the pixels is small enough to avoid overlap due to crowding.
Together these results demonstrate the organ specific differences
of MC&M-associated pixel classes.
The Combined mIF and mIHC Plexody
Assay
As a next step, we built a prototype assay that consisted of the
5-plex mIF, followed by a 3-plex mIHC assay. This assay, which
we named PLEXODY, was used to map the spatial characteristics
of MC&M populations in tumor areas and their relationships
to tumor and T cells. As a proof-of-principle application we
stained three cases each of pancreatic, prostate and kidney cancer.
After automated staining of one slide per case, the tissue was
scanned on the TissueFaxs. Digital IHC images were acquired
on the Vectra 2.0 multispectral imaging system and colors were
unmixed using the InFormTM software. The tiles fromTissueFaxs
and Vectra were co-registered based on nuclear outlines to
generate the dataset for analysis.
The analysis first focused on tissue areas positive for CD68,
CD163, CD11b and CD11c. Again, CD206 staining, which
appeared in MC&Ms and endothelial cells of tumor vasculature
(Supplementary Figures 4–12) was only analyzed underneath
the MC&M-mask. Figure 4 shows the results of 9 cancer
cases, illustrated in Supplementary Figures 4–12. Across cancer
types, percentages of single positive CD68+ and CD163+
pixels, ranged from 6.5 to 62.7%, while CD11b+ and CD11c+
single pixels ranged from 0.65 to 11%. Percentages of double
and higher level positive pixels (P2,3,4,5) comprised 9.7–
56% of the MC&M-mask. (Figure 4A, Supplementary Table 4).
Next, we further dissected the P2,3,4,5+ pixel populations by
quantifying four double positive pixel classes, CD68+/CD163+,
CD68+/CD11b+, CD68+/CD11c+, and CD163+/CD11c+.
The CD68+/CD163+ class was most abundant, comprising 40–
92% of all P2 pixels (Figure 4B, Supplementary Table 5). The
higher order colored pixels stained with 3–5 antibodies occupied
3.8–21.8% of the P2 positive pixel area. From these data, we
conclude that the majority of the P2,3,4,5 pixel group are positive
for 2 colors.
Next, we quantified pixel classes underneath the CD68+ and
CD163+ pixel masks as illustrated in Figure 2E (Figures 4C,D,
Supplementary Tables 6, 7). Approximately 23–85% of pixels
underneath the CD68-mask were single color. The most
abundant double positive pixel class was CD68+/CD163+
and the most abundant triple positive pixel class was
CD68+/CD163+/CD206+ (up to 29% of CD68-mask in a case of
prostate cancer, Supplementary Table 6). Interestingly, a unique
feature in renal cancer was an abundance of CD68+/CD11c+
(2.2–13% of the CD68-mask) and CD68+/CD163+/CD11c+
(3.5–15%) pixels. We also analyzed pixels underneath the
CD163-mask. Similar to CD68+ pixels, the majority of
CD163+ pixels were single positive (6–72% of CD163-masks).
However, in some cases, double positive CD163+/CD68+
pixel frequencies exceed those of single positive pixels.
As expected high frequencies of CD163+/CD206+ and
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FIGURE 4 | MC&M-associated pixel classes in cancers from pancreas, prostate and kidney. MC&M-associated pixel classes at a frequency of >3% are shown for
three cancer types (pancreatic ductal adenocarcinoma, prostate adenocarcinoma, and clear cell renal cell carcinoma). (A) Single positive MC&M-associated pixel
classes. Pie charts show single color CD68+, CD163+, CD11b+ and CD11c+ pixels as a fraction of the MC&M-mask for each cancer case. The P2,3,4,5 fraction
includes all pixels colored by more than one antibody. (B) Double positive MC&M-associated pixel classes. Pie charts show double positive pixel classes within the
P2, 3, 4, 5 pixel group for each cancer. In addition, the P3, 4, 5 fraction, which are pixels colored by more than two antibodies are shown. (C) Pixel classes within the
CD68-mask. Single, double and triple positive pixels are shown as a fraction of all CD68+ pixels (CD68-mask). (D) Pixel classes within the CD163-mask. Single,
double and triple positive pixels are shown as a fraction of the CD163+ pixels (CD163-mask). Values in pie-charts, standard deviations and number of tiles analyzed
per case are in Supplementary Tables 4–7.
CD163+/CD206+/CD68+ pixels were observed. Interestingly
we observed two cancer groups with regards to the frequencies
of CD163+/CD206+ pixels, independent of cancer type. The
high CD163+/CD206+ cancer group consisted of 4 cases (one
pancreas, two prostate, one kidney cancers) with 11.5–26.3% of
the CD163 mask comprised of CD163+/CD206+ pixels. The
low CD163+/CD206+ included the other 5 of the 9 cancer cases
with frequencies of CD163/CD206+ pixels less than 3% of the
CD163-mask. In summary, the analysis of MC&M-associated
pixel classes revealed a large amount of heterogeneity within and
across cancer types with no clear patterns that are cancer type
specific.
Since we did not observe cancer specific patterns of MC&M-
associated pixel classes, we questioned whether pixels differ
in spatial organization. We employed the PLEXODY assay to
generate tissues stained with the five MC&M-related antibodies,
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FIGURE 5 | Multiplex antibody staining with sequential IF and IHC (PLEXODY
assay). Fluorescent and chromogenic masks from each tile are integrated into
a single dataset. (A) Percentage of tissue area occupied by cancer, and
positive for cytokeratins 8/18. Standard deviations are indicated by the line
above each bar. In prostate cancer cases, tumor and normal glands were
separated based on mIHC with E34β12, an antibody binding to
high-molecular weight cytokeratins in basal cell of normal glands.
Corresponding representative digital images of mIF and mIHC in
Supplementary Figures 4–12. Values and tile numbers in
Supplementary Table 8. (B) Percentage of tissue area encompassed by
MC&M-mask stained by mIF. (C) Percentage of tissue area positive for CD3.
and in addition with antibodies against high and low molecular
weight cytokeratin and CD3. To prepare image tiles for analysis,
IF and IHC tiles were co-registered based on overlapping DAPI
and hematoxylin nuclear intensities [Supplementary Figure 13,
(39)]. In these tiles, the tumor area comprised 38.6–98.1% of the
tissue (Figure 5, Supplementary Table 8), while the tissue area
occupied by MC&M and T cell associated pixels amounted up to
16.0 and 16.5%, respectively.
Next, MC&M-associated pixel densities were determined
inside and outside the tumor (Figure 6A). Inside the tumor,
densities of MC&M-associated pixels ranged from 3.4 to 14.5%
(Figure 6B, Supplementary Table 9). Amongst pixel classes,
CD68+ and CD163+ pixels predominated over CD11b+ and
CD11c+ pixels (Figure 6B, Supplementary Table 10). CD68+
comprised between 25 and 94% of pixels within theMC&Mmask
inside the tumor (Figures 6C,D, Supplementary Table 10).
Interestingly, the correlations between CD163+ pixels and either
CD11b+ or CD11c+ pixels inside the tumor were r = 0.51
and r = 0.44, respectively, while other pairwise correlations
were less than r = 0.2. Finally, we compared densities of
MC&M-associated pixel classes in tumor and stromal regions
(Figure 6E, Supplementary Table 11). In 11/27 cases, densities
were greater in the tumor region compared to the stroma. For
each antibody, there were more cases with a greater density
of MC&M-associated pixels inside the tumor compared to the
stroma, suggesting that MC&Ms are recruited into tumor areas.
In addition to local densities of MC&M-associated pixels, we
measured their distances from the edge of the tumor (Figure 6F,
Supplementary Table 12). Interestingly, distances varied by pixel
class, but not by cancer type. Data were generated for prostate
and pancreas, but not for renal cancer because of the tumor
growth pattern. An average 70% of CD68+ and CD163+ pixels
were between 0 and 20 microns from the tumor edge. In contrast,
only 40% of CD11b+ pixels and 36% of CD11c+ pixels were
within 0 and 20 microns of the tumor boundary, with most pixels
at a greater distance from the tumor. CD11b+ and CD11c+
pixels were identified at a 240-micron distance, while CD68+ and
CD163+ pixels did not exist more than 180 microns away from
the tumor. In summary, densities of CD68+ and CD163+ pixels
are greater within and close to the edge of the tumor, consistent
with attraction of macrophages by the tumor while CD11b+ and
CD11c+ pixels reside at a greater distance from the tumor.
In addition to analyzing the spatial relationship of MC&M-
associated pixel populations and tumor cells, we performed a
similar analysis for pixel classes and CD3+ T cells. In co-
registered IF and IHC tiles, we identified the T cell mask
based on positive staining for CD3 (Figure 7A). Compared
to tumor areas with a maximal density of 14.5% of MC&M-
associated pixels, MC&M-associated pixel densities underneath
the T cell mask ranged between 18.5 and 51% (Figure 7B,
Supplementary Table 13). Similar to the cancer regions, most
MC&M-associated pixels in contact with T cells were CD68+
and CD163+. The average percentage of CD68+ and CD163+
pixels overlapping with CD3+ pixels was 53.6 and 58.3%,
respectively (Figure 7C, Supplementary Table 13). In contrast,
the percentage of CD3+ and CD11b+ or CD11c+ overlapping
pixels averaged only 8 and 7.7%, respectively (Figure 7D,
Supplementary Table 14). Mean distances from the T cell border
amounted to 21.2 microns and 28.6 microns, respectively, for
CD68+ and CD163+ pixels, while CD11b+ and CD11c+ pixels
were on average 77.5microns and 59microns away from the CD3
mask (Figure 7E, Supplementary Table 15). Altogether, the data
demonstrate higher densities and closer proximities of CD68+
and CD163+ pixels in tumor and T cell regions compared to
CD11b+ and CD11c+ pixels.
DISCUSSION
We established a multiplexed fluorescent and chromogenic
tissue staining assay, named PLEXODY, in which we apply
up to 8 antibodies on tissue sections using a fully automated
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FIGURE 6 | Spatial mapping of MC&M-associated pixel classes. (A) Workflow
diagram of overlay between chromogenic cancer mask and fluorescent
(Continued)
FIGURE 6 | CD163-mask. (B) Density of MC&M mask in tumor area. For each
cancer case, labeled 1, 2, or 3, the MC&M-associated pixel density
underneath the tumor mask is shown by the bar. N = 6–10 tiles/case.
Standard deviations are shown in Supplementary Table 9. (C) Densities of
MC&M-associated pixel classes in tumor area. For each MC&M-associated
pixel class, positive pixels underneath the tumor mask are divided by the area
of the tumor mask. N = 6–10 tiles/case. Standard deviations are shown in
Supplementary Table 9. (D) Percentage of MC&M-associated pixel classes
underneath the tumor mask. The percentage of CD68+, CD163+, CD11b+,
and CD11c+ pixels of the MC&M-mask in tumor areas is shown (n = 6–10
tiles per cancer type). Positive pixels include single, double, triple and higher
order positive pixels. Standard deviations are shown in
Supplementary Table 10. (E) Tumor: stroma densities of MC&M-associated
pixel classes. Ratio of MC&M-associated pixel densities in the tumor (B) and
MC&M-associated pixel density in the stroma. Stromal pixels are calculated by
subtracting pixels in tumor area from total pixels in tissue. Standard deviations
are shown in Supplementary Table 11. The dashed line refers to an equal
density of colored pixels in the tumor and stroma (F). Distance measurements.
Schematic representation of distance measurements between nuclei at the
tumor border and CD163+ pixel clusters. The segmentation of tumor nuclei is
shown in the left panels. A representative measurement of the distance
between a nucleus and the closest MC&M-associated pixel group is shown in
the right panel. Histograms of tumor–MC&M-associated pixel distances in
prostate (n = 25 tiles) and pancreas (n = 23 tiles) cancers. The average
percentages of tumor–MC&M-associated pixel distances (y-axis) in a distance
interval (x-axis) are shown with the standard deviations. Separate values for
prostate and pancreatic cancer types are in Supplementary Table 12.
staining process. The mIF panels requires a 14-h staining
program and the mIHC, an 8-h staining cycle. After co-
registration of digital images from slides stained sequentially
with CD68, CD163, CD206, CD11b and CD11c by mIF and
with high molecular weight CK (clone 34E1β2), CK8/18 and
CD3 by mIHC, we generated intersecting masks of up to 3
pixel colors and measured single, double and triple positive
pixels defining 25 MC&M-associated pixel classes. While the
IF component provides opportunities for visualization of multi-
color MC&M-associated pixel classes, the IHC component adds
diagnostic accuracy. Since commercial software applications are
based on nuclear segmentation for quantification of multicolor
digital slides, the stellate morphology and dendritic nature
of some MC&M subtypes hinder the nuclear quantification
approach. Therefore, we pursued an area-based quantification
that does not rely on nuclear segmentation (Figure 2). Spatial
distribution of MC&M-associated pixels differed between two
normal tissue sources and between normal and cancer. In
addition, the data provide novel insights into tumor associated
MC&M populations: (i) the majority of MC&M-associated
pixels are colored with only one antibody; (ii) CD68+/CD163+
predominate amongst double and triple labeled pixels; (iii)
elevated frequencies of CD68+/CD163+/CD11c+ pixels are
identified solely in renal cancers; (iv) across the three cancer
types in most cases, densities of MC&M-associated pixels are
greater in the tumor region compared to the surrounding
stroma; (v) densities of CD68+ and CD163+MC&M-associated
pixel classes in tumor regions and in contact with CD3+
T cells are greater than densities of CD11b+ and CD11c+
pixel classes and (vi) distances of CD68+ and CD163+ pixel
clusters to the edge of the tumor and to CD3 cells are shorter
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FIGURE 7 | Spatial relationships of MC&M-associated pixel classes and
CD3+ T cells. (A) Workflow diagram of overlay of CD3+ T cell mask and
CD163-mask in tile labeled IHC/IF and illustration of distance measurement.
(B) Densities of antibody masks in direct contact with T cells. For each cancer
case, labeled 1, 2, or 3, the MC&M-associated pixel density underneath the
CD3-mask is shown by the bar. N = 6–10 tiles/case. Standard deviations are
shown in Supplementary Table 13. (C) Densities of MC&M-associated pixel
classes in direct contact with T cells. For each MC&M-associated pixel class,
positive pixels underneath the CD3 mask are divided by the area of the CD3
mask. N = 6–10 tiles/case. Standard deviations are shown in
Supplementary Table 13. (D) Percentage of MC&M-associated pixel classes
underneath CD3 mask. The percentage of CD68+, CD163+, CD11b+, and
CD11c+ pixels of the MC&M-mask in contact with T cells is shown (n = 6–10
tiles per cancer type). For each antibody, positive pixels include single, double,
triple and quadruple positive pixels. Standard deviations are shown in
Supplementary Table 14. (E) Mean distances between T cells and
MC&M-associated pixel classes. Distances were measured as shown in (A).
The mean distance and standard deviation are shown for each case and
antibody in Supplementary Table 15.
compared to CD11b+ and CD11c+ pixel clusters. Altogether,
a pattern emerges demonstrating similarities in staining and
spatial organization of MC&M-associated pixel populations
across these three cancer types. However, the densities and spatial
organization of CD68+ and CD163+ MC&M-associated pixel
classes vs. CD11b+ and CD11c+MC&M-associated pixel classes
differ considerably.
Excellent recent reviews describe the complexity of
MC&M subtypes in the tumor microenvironment (1, 2). The
nomenclature of MC&M subtypes in human tumors is evolving
as ontogenic and functional characteristics are being linked to
phenotypes defined by expression of surface markers. A major
distinction amongst tumor associated macrophages (TAMs)
exists between M1, pro-inflammatory macrophages, identified
by CD68+ staining, and M2 macrophages with pro-metastatic,
immunosuppressive and pro-angiogenic activities that express
CD163 and CD206 (43). In addition to TAMs, CD11b+ and
HLA-DR-negative monocytic and granulocytic bone marrow
derived myeloid cells infiltrate tumors and promote severe
immune dysfunction (44). CD11c is expressed on dendritic cells.
While stimulating tumor growth, metastasis and angiogenesis in
an immature state, upon differentiation, CD11c+ macrophages
acquire potent antigen presenting and anti-tumor functions
(45). Dual antibody staining using anti- CD11b and anti-CD11c
improved the subtyping of acute myelogenous leukemia and
evaluation of treatment response with in vivo and in vitro
correlations (46).
A mixed M1/M2 macrophage phenotype has been observed
in kidney cancer (47), which in our profiling study also expresses
abundant CD11c (Figure 4D). Our study demonstrates that this
MC&M subtype is more abundant at the periphery of tumors
and at a greater distance from T cells (Figures 6E, 7D). When
comparing stromal and intratumoral MC&M-associated pixel
densities, it appears that all pixel classes are increased inside
compared to outside the tumor (Figure 6D), suggesting that
tumors might exert mechanisms to attract cells marked by
MC&M-associated pixel classes.
The PLEXODY staining assay that we piloted can be used
with up to 10 antibodies per slide. Compared to manual or
automated cyclic staining systems (48, 49), or to hyperplexed
systems such as cyclic immunofluorescence (50), tissue mass
cytometry (51), nCounter R© applied to tissues and CODEX (52),
the throughput of PLEXODY is greater. Up to 30 slides can
be automatically stained with 5 antibodies using an overnight
staining program. A major advantage of our method is the signal
amplification through the tyramide amplification system used in
the PLEXODY assay. While this extent of amplification may not
be required for antibodies reactive with abundantly expressed CD
antigens, when using the assay to measure the activation of signal
transduction pathways or the localization of transcription factors,
a highly amplified protocol is necessary (53).
At this time, the rate limiting step in the PLEXODY assay is
the slide scanning. To optimize the efficiency of the workflow,
we preselect regions for scanning. Scanning only regions that will
be analyzed, significantly reduces the scanning time. However,
this requires careful planning of data acquisition and analysis,
since the IF signals are labile. While the mIHC component of
the PLEXODY assay is permanent, the mIF is destroyed during
the mIHC staining. Therefore, all the IF scanning and quality
control has to be finalized before embarking on the IHC. When
left untouched, the mIF slides are stable for weeks and months
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in the refrigerator, allowing to complete the mIF portion of
the assay without a time constraint. After scanning, digital IF
images provide a large dataset that can be reanalyzed to answer
additional questions in future projects.
The application and proof-of-principle of the PLEXODY
assay provided a deeper insight into the spatial organization
of tumor associated MC&M-associated pixel classes. Previously
published validation studies of the multiplex technology that
included CD68 as a macrophage marker utilized a qualitative
review of images to validate antibody staining patterns (28).
We adopted the same approach that was used by these authors
to demonstrate the staining specificity of our MC&M antibody
panel (Figure 1D). Interesting, the outlines of CD68+ cells
are identical in both studies, further confirming the antibody
specificity and threshold settings of the anti-CD68 antibody
reagent. The workflow of PLEXODY lies between the commercial
multiplex staining and imaging with the OPAL/Vectra system
that includes a proprietary staining kit and color deconvolution
software and the open source system reported by Blom et al.
(29). While the staining component of PLEXODY is automated,
the data generation utilizes Matlab algorithms. We anticipate
that the ability of the Matlab code for image co-registration
and intersecting of single color pixel maps will be adopted in
the future by one of the commercial analytics companies. This
will allow our approach to be used for image analysis without
requiring programming expertise.
In a different report, an extensive, quantitative and opened
source immunophenotyping pipeline that is similar to our
approach included a combination of 8 fluorescent and
chromogenic antibodies, was applied to the same tissue
section of a prostate cancer tissue microarray (29). Several
important technical advances were accomplished in this study,
such as whole slide co-registration of mIF and mIHC, nuclear
segmentation and cell classification based on expression of
CD45, CD4, CD8, FoxP3, Ki-67, androgen receptor, alpha-
methyl-CoA racemase, cytokeratin 5, 8 and 18, E-cadherin
and p63, and an integrative analysis of the entire multiplexed
dataset from the whole slide. While this study is based on
nuclear segmentation of lymphocytes, the approach in our
study is based on a pixel based segmentation of myeloid
cells and macrophages. To generate the T cell mask, we also
apply the nuclear segmentation method. Choosing the right
method to generate cellular masks depends on the morphology
of cells. Cells with a dendritic morphology (macrophages,
neurons, mesenchymal cells) require selection of an appropriate
image analysis method to capture the signal from cellular
processes.
A systems pathology approach was applied by Bruck et al.
(54) to demonstrate the relationship between treatment response
and cellular organization in the tumor microenvironment
of chronic myelogenous leukemia. Integrative data analysis
using quantitative measurements of slides stained with a
fluorescent 5-plex and chromogenic 3-plex revealed an
immunosuppressive tumor microenvironment and adverse
outcomes for patients with a low percentage of CD4+ and high
percentage of PD1+/TIM3-/CD8+ T cells (54). Including data
from mIF/mIHC measurements in the outcomes prediction
model outperformed conventional stratification by BCR-ABL
PCR-based quantification (54).
Another example of the power of the multiplex analytical
approach is demonstrated in a study of lung cancer biopsies (32).
Distances between tumor and CD8+ cells and ratios of cytotoxic-
to-regulatory T cells predicted response to treatment and patient
outcomes. Another recent, elegant study in Hodgkin’s lymphoma
provided a detailed mapping of distances between tumor
associated macrophages, labeled with CD68 and CD4+/CD8+
T cells (55). Measurements of PD-1 and PD-L1 expression
were also included in this study providing important, treatment
related information. Further, the authors demonstrated specific
cell-cell interactions by measuring Euclidian distances between
cell populations. The data from this study revealed that PD-
L1+/CD68+ TAMs reside in the vicinity of T cells and that
CD4+ T cells expressing PD-1 aggregate around Reed Sternberg
cells (55).
There are several limitations of our study. Unfortunately,
we were not able to determine the actual cell numbers of
MC&Ms. The numbers of pixels associated with each cell may
vary and counting macrophages, which are 20–80 microns in
length, requires a 3-dimensional visualization technique. This
can potentially be accomplished with tissue clearing protocols
(56) and imaging via confocal or light sheet microscopes (57).
However, these approaches are low throughput and difficult
to standardize. Another limitation is the thresholding of the
fluorescent images. While we tested automated thresholding
systems, we could not find one that reproduces the manual
thresholding. Therefore, thresholds need to be optimized by
the laboratory performing the image analysis. Finally, another
limitation is the dependence of the signal intensity on the
amplification reagents. The commercial secondary antibody we
used is conjugated to a high numbers of horse radish peroxidase
(HRP) molecules. Other vendors may differ in the ratio of
antibody to HRP molecules, which directly effects the brightness
of the stain. Thus, while the method and PLEXODY pipeline
remains the same when using reagents from other sources,
percentages of cell populations may decrease due to loss of low
intensity pixels.
In summary, we demonstrate the feasibility of an automated
staining process, combined with image co-registration, digital
image analysis and data integration from whole slides. Modules
of multiplex staining, image acquisition and processing and
data extraction and analysis are combined to provide a high
content dataset of MC&M-associated pixel classes in the
tumor microenvironment. As demonstrated in other studies,
measurements of immune cell densities and distances provide
important insights into cellular interactions before treatment,
are predictive of treatment responses. In addition, the spatial
organization of immune cells was shown to be affected by
cytokines that are released by macrophages or cancer cells (58–
60). While we applied the PLEXODY assay to profile MC&M-
associated pixel classes, it can also be used for measurements of
pathway activation and transcriptional activity by using different
panels of antibodies. Thus, due to its efficiency and automation,
the PLEXODY assay has broad applicability for translational
research studies that consist of large cohorts of patients.
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